The PRAME immunotherapeutic had a clinically acceptable safety profile at all 3 doses investigated, consistent with another phase I study conducted in patients with non-small-cell lung cancer (NSCLC) in which no DLT was observed.12 The results of both studies, together with results of studies of the MAGE-A3 immunotherapeutic,13–15 support the acceptable safety profile of antigen-specific cancer immunotherapies. The gene discussed is MAGEA3; the disease is cancer.